TFMB-(R)-2-HG |
| Katalog-Nr.GC38199 |
TFMB-(R)-2-HG, eine zellmembrangÄngige Version von (R)-2-HG, ist ein karzinogener Faktor bei akuter myeloischer LeukÄmie (AML). TFMB-(R)-2-HG beeintrÄchtigt SCF ER- Differenzierung von Hoxb8-Zellen als Reaktion auf Östrogenentzug.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1445700-01-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TFMB-(R)-2-HG, a cell membrane-permeable version of (R)-2-HG, is a carcinogenic factor in Acute myeloid leukemia (AML).TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cells differentiation in response to estrogen withdrawal[1].
[1]. Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339(6127):1621-5.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *